Myocardial Infarction Treatment Market: Poised for Expansion to USD 3.8 Billion by 2030 | Credence Research
The Global Myocardial Infarction Treatment Market has witnessed steady growth in recent years, with projections indicating a compound annual growth rate (CAGR) of 8.30% from 2023 to 2030. Valued at USD 2.2 billion in 2022, the market is forecasted to reach USD 3.8 billion by 2030.
A heart attack, medically referred to as myocardial infarction, occurs when the blood supply to the heart muscle is abruptly interrupted, leading to tissue damage. This life-threatening event typically arises when one or more coronary arteries become obstructed, often due to the buildup of plaque comprising fats, cholesterol, and cellular waste. Symptoms of myocardial infarction include sweating, nausea, heartburn, and chest discomfort. Various risk factors, such as age, smoking, high blood pressure, obesity, diabetes, illegal drug use, and stress, can promote the accumulation of fatty deposits (atherosclerosis), narrowing arteries throughout the body, potentially resulting in heart attacks. Treatments for heart attacks and associated risks include medications like aspirin, antiplatelet drugs, and stress-relief medications. Additionally, drugs like PTA and stents are employed to treat artery blockages. A procedure known as a cardiac artery bypass might be performed if necessary to re-establish blood flow to the heart muscle.
Driving Factors
The consistent introduction of new product approvals is poised to drive the myocardial infarction market. Regular advancements in the sector lead to more product releases and market growth. Furthermore, there’s a significant surge in global public campaigns and initiatives focused on raising awareness about cardiovascular diseases, which is expected to accelerate the market’s growth. Alarmingly, statistics from the Centers for Disease Control and Prevention reveal that every 34 seconds, a person in the U.S. succumbs to cardiovascular disease (CVD). In 2020, one in every five deaths in the U.S. was attributed to heart disease, approximating 697,000 fatalities. The increasing number of clinical studies for castrate-resistant prostate cancer treatment in the coming years is also projected to bolster the myocardial infarction market. The escalating rates of high blood pressure, obesity, smoking, and physical inactivity are predicted to increase the cases of cardiovascular diseases, further promoting the growth of the myocardial infarction market.
Restraining Factors
On the downside, stringent regulatory policies in the healthcare sector could impede the market’s growth. High costs associated with clinical trials may also deter expansion. A rise in overall healthcare expenditure is another factor that might curtail growth.
Recent Developments
- In May 2021, Recardio Inc., a clinical-stage biotech company focused on regenerative treatments for cardiovascular diseases, completed its Phase 2 study of dutogliptin in conjunction with filgrastim for early recovery post-myocardial infarction.
- In May 2020, Eli Lilly and Company, Boehringer Ingelheim, and the Duke Clinical Research Institute (DCRI) announced a collaborative academic research for EMPACT-MI, examining the role of EMPAgliflozin post acute myocardial infarction.
Dive Deeper into the Data: Download the Comprehensive Myocardial Infarction Treatment Market Report Today!
Key Market Trends
Nanoparticle technology, offering innovative methods to deliver medications and imaging probes, presents novel opportunities for treating cardiovascular diseases (CVD). Significant efforts are being channeled into exploring treatment options for myocardial infarction (MI). With advancements in nanoparticle production and design versatility, they are being increasingly used in preclinical CVD research. Rational design of nanoparticles allows the development of nanocarrier systems with precise targeting capabilities, addressing challenges such as poor bioactive factor delivery efficiency, biological barrier crossing issues, ineffective bioimaging, and adverse off-target effects. Notably, endeavors to control inflammation, promote angiogenesis, and expedite tissue regeneration are pushing the boundaries of therapeutic and diagnostic solutions for MI-related challenges.
Prominent Market Players
Some of the leading players in the market include:
- Bristol-Myers Squibb Co.
- Bayer AG
- Johnson & Johnson Services Inc.
- Sanofi S.A.
- Novartis International AG
- AstraZeneca plc.
- Daiichi Sankyo Co Ltd
- Boehringer Ingelheim International GmbH
- Pfizer Inc
- Merck KGaA
- Among others.
Segmentation
- By Drug Class
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic Blockers
- Vasodilators
- Angiotensin-converting Enzyme (ACE) Inhibitors
- Angiotensin-receptor Blockers
- Analgesics
- Thrombolytics
- By Route of Administration
- Oral
- Injectable
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- USA
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Dive Deeper into the Data: Download the Comprehensive Myocardial Infarction Treatment Market Report Today!
Browse More Related Reports:
Myocardial Infarction Treatment Market
Patient Access Solutions Market
About Us:
Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.
Media Contact
Company Name: Credence Research
Contact Person: Gunakesh Parmar
Email: Send Email
Phone: +91 6232493207
City: Gwalior
State: MP
Country: India
Website: https://www.credenceresearch.com/
